Eli Lilly
Insulin prices, a Medicaid fraud verdict, Zyprexa and the GLP-1 wars
Eli Lilly is now one of the world's most valuable drugmakers, largely on the strength of its GLP-1 obesity and diabetes medicines. It is also a defendant in one of the most sustained pricing controversies in US healthcare: the rising cost of insulin. Lilly has faced a whistleblower verdict over Medicaid rebates, a record criminal fine over the antipsychotic Zyprexa, and escalating legal fights over GLP-1 compounding and advertising.
Questions
Why is Eli Lilly considered controversial?
The world's best-selling insulin Humalog rose from $21 in 1999 to $274 in 2017; Lilly pleaded guilty over Zyprexa and lost a Medicaid fraud verdict now exceeding $220 million; and its GLP-1 dominance has generated false advertising and price litigation.
Lilly is one of three companies, alongside Novo Nordisk and Sanofi, that supply more than 90% of the world's insulin, and it has been sued repeatedly for allegedly inflating insulin prices in concert with pharmacy benefit managers. Its best-known insulin, Humalog, cost $21 in 1999 and $274 in 2017. Lilly also lost a whistleblower case alleging it underpaid Medicaid rebates, a judgment now exceeding $220 million after the Supreme Court declined to hear its appeal.
Q2What did Eli Lilly plead guilty to over Zyprexa?
Lilly paid $1.415 billion — including a then-record $515 million criminal fine — for promoting its antipsychotic Zyprexa for unapproved uses including treating dementia in elderly people, following four whistleblower lawsuits from former sales representatives.
In January 2009 Lilly agreed to plead guilty and pay $1.415 billion for promoting its antipsychotic Zyprexa for uses the FDA had not approved, including treating dementia and Alzheimer's dementia in elderly people. The resolution included a $515 million criminal fine, then the largest ever in a health care case, and up to $800 million in civil payments to federal and state programmes such as Medicaid.
Q3What did a jury find about Lilly and Medicaid rebates?
A federal jury found Lilly liable under the False Claims Act for underpaying Medicaid rebates, awarding $61 million trebled to $184 million — a judgment exceeding $220 million with interest after the Supreme Court declined to hear Lilly's appeal.
In a case brought in 2014 by Ronald Streck, a former wholesaler executive, a federal jury in 2022 found Lilly liable under the False Claims Act for underpaying Medicaid rebates. The allegation was that Lilly made retroactive price increases and miscalculated its average manufacturer price, reducing the rebates it owed. The jury awarded $61 million, which was trebled to about $184 million.
Q4How has Lilly been implicated in the insulin pricing controversy?
A Senate investigation found Lilly and rivals raised insulin prices in lockstep; internal documents showed executives were sensitive to PBM rebate economics; and Florida's 2026 lawsuit alleges Lilly returns roughly $210 of every $280 Humalog vial to PBMs as rebates.
A two-year Senate Finance Committee investigation, published in 2021, found insulin list prices had doubled or tripled in a decade without meaningful improvements in the drugs, and that executives at Lilly and Novo Nordisk were sensitive to the fact that PBMs earn money from rebates and fees linked to list prices. When the FTC sued the three largest PBMs in 2024, its competition bureau said it remained deeply troubled by the role of Lilly, Novo Nordisk and Sanofi and could sue manufacturers in future.
Q5Has Lilly lowered its insulin prices?
Yes — in March 2023 Lilly cut Humalog's list price by 70% from $274.70 to $66.40 and capped out-of-pocket costs at $35 a month, following years of increases and mounting legal and political pressure.
Yes, substantially. In March 2023 Lilly announced it would cut the list prices of Humalog and Humulin by 70% and cap out-of-pocket costs at $35 a month for many patients. The list price of a 10mL Humalog vial fell from $274.70 to $66.40, and its unbranded insulin lispro dropped to $25 a vial. The cuts came amid heavy political pressure and followed the Inflation Reduction Act's $35 monthly cap for Medicare patients.
Q6What controversies surround Lilly's GLP-1 drugs?
List prices around $1,000 a month, lawsuits against compounders selling cheaper copies during shortages, and a November 2025 government deal setting a $245 Medicare price — with critics questioning the transparency of the arrangement.
Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, faces several disputes. Its list price, like rival Wegovy's, was around $1,000 a month, putting it out of reach for many uninsured patients. During shortages, compounding pharmacies sold cheaper copies; Lilly responded with lawsuits, including one against Seattle clinics that allegedly marketed compounded tirzepatide under a Zepbound-branded programme.
Q7Why did Novo Nordisk sue Eli Lilly?
On July 21, 2026, Novo filed a false advertising lawsuit alleging Lilly's TV and social media campaigns compare the highest tirzepatide doses with lower Wegovy doses while omitting Novo's newer 7.2mg version approved in March 2026.
On July 21, 2026 Novo Nordisk filed a false advertising lawsuit in New Jersey federal court against Lilly. Novo alleges Lilly's national TV and social media campaigns for Zepbound and Mounjaro compare the highest doses of Lilly's drugs with lower doses of Wegovy and Ozempic while omitting newer, higher-dose versions, including a 7.2mg Wegovy dose approved in March 2026. Novo says the ads have generated about 700 million impressions and is seeking a preliminary injunction, corrective advertising and damages.
Q8Is Lilly facing new lawsuits over insulin?
Yes — the federal multidistrict litigation had 416 pending cases as of mid-2025, and Florida's September 2026 suit extends the rebate theory to GLP-1 products, signalling states may apply insulin-pricing logic to the far more lucrative obesity drug market.
Yes. The insulin litigation has broadened rather than narrowed. As of mid-2025, 416 lawsuits were pending in the federal multidistrict litigation over insulin pricing, brought by states, counties, cities, school boards and self-funded employers.
Q9How has Lilly defended its insulin record?
Lilly argues the system — not manufacturers — created affordability problems, and points to its 2023 price cuts, its $35 cap at 85% of US pharmacies, and an unbranded lispro at $25 per vial, cheaper than a Humalog vial in 1999.
Lilly argues that the healthcare system, not manufacturer greed, created affordability problems, and that it has moved faster than rivals to fix them. Announcing its 2023 price cuts, CEO David Ricks said the system still does not provide affordable insulin for everyone and "that needs to change". He called on others to "meet us at this point" and said the cuts had been planned for some time.
Q10How dominant has Lilly become in the obesity drug market?
In Q1 2026, Zepbound recorded $4 billion in sales versus about $2.7 billion for Wegovy — and Novo's July 2026 false advertising lawsuit is in part a response to Lilly's comparative advertising based on the SURMOUNT-5 head-to-head trial.
Lilly has overtaken Novo Nordisk, which was first to market with Wegovy. In the first quarter of 2026, Zepbound recorded $4 billion in sales compared with about $2.7 billion for Wegovy. Lilly's medications have become the preferred treatments among many providers and patients because of their high efficacy, and its advertising leans on the SURMOUNT-5 trial, which showed 2.4mg Wegovy produced 47% less relative weight loss than Zepbound.
Q11What is the overall picture of Eli Lilly's controversies?
Two tracks: historical cases largely resolved (Zyprexa guilty plea, Streck Medicaid verdict), and ongoing structural litigation over whether insulin makers and PBMs jointly inflated list prices — a theory now expanding to GLP-1 drugs.
Lilly's controversies sit on two tracks. The first is historical and largely resolved: the Zyprexa guilty plea and the Streck Medicaid verdict show courts and prosecutors finding against the company. The second is ongoing and structural: litigation over whether insulin makers and PBMs jointly inflated list prices, and new disputes over GLP-1 pricing, compounding and advertising.